Quadrant Capital Group LLC increased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,345 shares of the pharmaceutical company’s stock after purchasing an additional 148 shares during the quarter. Quadrant Capital Group LLC’s holdings in GlaxoSmithKline PLC were worth $162,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of GlaxoSmithKline PLC by 5.9% in the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares during the period. Fisher Asset Management LLC raised its holdings in shares of GlaxoSmithKline PLC by 4.7% in the 2nd quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after purchasing an additional 564,519 shares during the period. Renaissance Technologies LLC raised its holdings in shares of GlaxoSmithKline PLC by 112.1% in the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the period. Hotchkis & Wiley Capital Management LLC raised its holdings in shares of GlaxoSmithKline PLC by 4.3% in the 2nd quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after purchasing an additional 322,700 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of GlaxoSmithKline PLC by 15.8% in the 1st quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the period. 9.28% of the stock is currently owned by institutional investors.

GSK has been the topic of a number of research reports. BidaskClub raised shares of GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 13th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Tuesday, July 18th. Morgan Stanley cut shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a report on Friday, September 8th. Finally, Argus reaffirmed a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a report on Thursday, August 31st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $44.67.

Shares of GlaxoSmithKline PLC (GSK) traded down 0.3283% during midday trading on Wednesday, reaching $40.6461. 1,562,240 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $40.19 and a 200-day moving average of $41.60. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54. The stock has a market cap of $99.96 billion, a price-to-earnings ratio of 39.3858 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities research analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 annualized dividend and a yield of 4.82%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-shares-bought-by-quadrant-capital-group-llc/1623682.html.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.